Header Logo

Connection

VICENTE VALERO to Triple Negative Breast Neoplasms

Back to Details
This is a "connection" page, showing publications VICENTE VALERO has written about Triple Negative Breast Neoplasms.
VICENTE VALERO
Connection Strength
2.139
Triple Negative Breast Neoplasms
  1. Carboplatin for early triple-negative breast cancer? Lancet Oncol. 2014 Jun; 15(7):676-8.
    View in: PubMed
    Score: 0.243
  2. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat. 2023 Jun; 199(3):457-469.
    View in: PubMed
    Score: 0.112
  3. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
    View in: PubMed
    Score: 0.112
  4. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg. 2023 07 01; 237(1):101-108.
    View in: PubMed
    Score: 0.111
  5. Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI. Sci Rep. 2023 01 20; 13(1):1171.
    View in: PubMed
    Score: 0.110
  6. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2022 Dec; 23(12):1517-1524.
    View in: PubMed
    Score: 0.109
  7. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.
    View in: PubMed
    Score: 0.106
  8. Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. J Magn Reson Imaging. 2022 12; 56(6):1901-1909.
    View in: PubMed
    Score: 0.105
  9. Mid-treatment Ultrasound Descriptors as Qualitative Imaging Biomarkers of Pathologic Complete Response in Patients with Triple-Negative Breast Cancer. Ultrasound Med Biol. 2022 06; 48(6):1010-1018.
    View in: PubMed
    Score: 0.104
  10. A model combining pretreatment MRI radiomic features and tumor-infiltrating lymphocytes to predict response to neoadjuvant systemic therapy in triple-negative breast cancer. Eur J Radiol. 2022 Apr; 149:110220.
    View in: PubMed
    Score: 0.104
  11. BI-RADS Ultrasound Lexicon Descriptors and Stromal Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Acad Radiol. 2022 01; 29 Suppl 1:S35-S41.
    View in: PubMed
    Score: 0.099
  12. Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer. Cancer. 2021 08 15; 127(16):2880-2887.
    View in: PubMed
    Score: 0.098
  13. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Res Treat. 2021 Jan; 185(1):1-12.
    View in: PubMed
    Score: 0.094
  14. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. Eur J Radiol. 2020 Sep; 130:109170.
    View in: PubMed
    Score: 0.093
  15. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.
    View in: PubMed
    Score: 0.081
  16. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
    View in: PubMed
    Score: 0.074
  17. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients. Ann Surg Oncol. 2016 May; 23(5):1515-21.
    View in: PubMed
    Score: 0.068
  18. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):102-10.
    View in: PubMed
    Score: 0.065
  19. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.
    View in: PubMed
    Score: 0.062
  20. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
    View in: PubMed
    Score: 0.060
  21. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40.
    View in: PubMed
    Score: 0.057
  22. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant. J Clin Oncol. 2020 02 10; 38(5):388-394.
    View in: PubMed
    Score: 0.022
  23. A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):777-783.
    View in: PubMed
    Score: 0.019
  24. Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control. 2016 Mar; 27(3):359-66.
    View in: PubMed
    Score: 0.017
  25. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol. 2014 Mar 10; 32(8):735-44.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.